La Salle

Researchers are investigating the safety, tolerability, pharmacokinetics, and early anti-tumor effects of new drugs or drug combinations given around the time of surgery (perioperative treatment) for people with locally advanced, operable gastric, gastroesophageal junction, or esophageal adenocarcinoma who have not previously been treated for their cancer. This Phase II study involves multiple centers and evaluates different novel treatments within separate sub-studies tailored to specific patient groups. Participants will be assigned to one of three sub-studies, each testing different novel agents or combinations approved by a Safety Review Committee. Treatments include intravenous infusions of drugs such as AZD0901, Rilvegostomig, and Trastuzumab Deruxtecan, as well as standard chemotherapy agents like Capecitabine (oral), 5-Fluorouracil (IV), and FLOT chemotherapy (IV). The study aims to find the recommended doses and assess the effects of these treatments given before and after surgery. Throughout the study, researchers will monitor participants for adverse events and serious side effects up to 38 months. They will also measure the percentage of participants who achieve a complete tumor response. Participants undergo regular assessments including physical exams, laboratory tests, and imaging to evaluate treatment effects and safety. The study is designed to provide detailed information on how well these new treatments work and how safe they are over a prolonged follow-up period.